Depression: all studies (page 350) - The Consciousness Library

Effects of mindfulness-based interventions on mental health among women with fetal loss: A systematic review and meta-analysis.

Midwifery July 15, 2025 Xin Wang, Ying Luo, Ying Gao et al.

Mindfulness-based interventions (MBIs) have shown potential in reducing maternal negative emotions, but their effectiveness for women with fetal loss requires further investigation. This study aimed to evaluate the effects of MBIs on mental health outcomes among these women. Randomized controlled trials (RCTs) on MBIs for women with fetal loss were retrieved from eight databases, covering...

DOI: 10.1016/j.midw.2025.104520 Full text Depression Fetal loss Mental health Mindfulness-based interventions

Biochemical Insights into Diverse Psilocybe Mushrooms and Their Metabolites as Sources of Neuroactive Agents: A Review.

Current microbiology July 15, 2025 Gokul Sudhakaran, Shreya Chakraborty, Ashok Kumar et al. 2 citations

Psilocybe species, commonly known as "magic mushrooms", are a group of hallucinogenic fungi known for their psychoactive compounds such as psilocybin, psilocin, baeocystin, and norbaeocystin. These species have been the focus of scientific study due to their potential therapeutic applications, despite their classification as controlled substances in many jurisdictions. This review aims to...

DOI: 10.1007/s00284-025-04379-8 Full text Depression Anxiety Addiction Psilocybin +20

Opioids diminish the placebo antidepressant response: Observational post hoc findings from a randomized controlled ketamine trial.

Journal of Affective Disorders July 15, 2025 Theresa R. Lii, Josephine R. Flohr, Robin L. Okada et al. 1 citation

The endogenous opioid system is thought to play a role in the placebo antidepressant response. A recent trial comparing the rapid antidepressant effects of ketamine versus placebo in surgical patients, some of whom were on chronic opioid therapy, revealed a substantial placebo effect. This finding provided an opportunity to test the hypothesis that opioid agonist exposure interacts with placebo...

DOI: 10.1016/j.jad.2025.04.008 Full text Opioids Depression treatment Opioid effects Placebo response +2

The antidepressant potential of (2R,6R)-hydroxynorketamine: A detailed review of pre-clinical findings.

European Journal of Pharmacology July 15, 2025 Isis Koutrouli, Kristýna Mazochová, Rachel R. Horsley 4 citations

Depression affects hundreds of millions globally, and in 2019, esketamine, an S-enantiomer of ketamine, was approved for treatment-resistant depression (TRD). While effective, esketamine carries risks, including abuse potential and adverse effects even at low doses. As a result, ketamine's metabolite, (2R,6R)-hydroxynorketamine ((2R,6R)-HNK), has garnered attention for its potential...

DOI: 10.1016/j.ejphar.2025.177604 Full text Behavioral despair Hydroxynorketamine Learned helplessness Pre-clinical +5

A feasibility study of a tailored mindfulness-based group intervention for psychological distress and adjustment for allogeneic hematopoietic stem cell transplant outpatients.

BMC cancer July 14, 2025 Litza Kiropoulos, Phuong Linh Dang, Vanja Rozenblat 3 citations

Mindfulness-based interventions have provided consistent benefits for the physical and emotional wellbeing of cancer patients. However, their feasibility has not been examined in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT), particularly in the post-transplant phase. The aim of this study was to examine the feasibility and acceptability of a six-week group-based...

DOI: 10.1186/s12885-025-14569-z Full text Anxiety Depression Mindfulness Bone marrow transplant +4

Effectiveness of an online mindfulness based stress reduction intervention on psychological distress among patients with COVID19 after hospital discharge.

Scientific Reports July 13, 2025 Maryam Mozaffari, Manijeh Naderi, Hosein Zahednezhad et al. 1 citation

Given the high prevalence of psychological complications during pandemics such as COVID-19, it is imperative to identify effective psychological interventions that can improve the mental health of patients and community members. The effectiveness of mindfulness-based intervention in discharged patients with infectious respiratory diseases, particularly during pandemics, has been examined in a...

DOI: 10.1038/s41598-025-11289-z Full text Anxiety Depression Psychological distress Covid-19 survivors +2

Microglial BDNF modulates arketamine's antidepressant-like effects through cortico-accumbal pathways.

Science Advances July 11, 2025 Lujuan He, Xuenan Wang, Shilin Luo et al. 8 citations

Arketamine, the (R)-enantiomer of (R,S)-ketamine, shows even greater rapid and sustained antidepressant-like effects in rodent models compared to esketamine, yet the underlying mechanisms remain unclear. In this study, we used the chronic social defeat stress (CSDS) model to investigate how arketamine exerts its antidepressant-like effects. We found that activating cAMP response element-binding...

DOI: 10.1126/sciadv.adv5986 Full text Arketamine Neuroplasticity Depression Microglia +15

Exploring the Frontiers of Psychedelics: A New Chromatographic Method for Detection and Quantification of Psilocybin and Psilocin in Psilocybe cubensis Mushrooms

ACS Omega July 10, 2025 Taynah Pereira Galdino, Lucas C Oliveira, Mateus A Luz et al. 5 citations

Innovative therapies, such as psilocybin-assisted psychotherapies, hold great promises for treating anxiety, depression, and various other mental health disorders, addressing some of the challenges faced by conventional psychiatric medicine. This study focuses on developing and validating an HPLC-DAD methodology for detecting psilocybin and psilocin in extracts from psychedelic mushrooms...

DOI: 10.1021/acsomega.5c02751 Psilocybin Psilocin Anxiety Depression +19

Naturalistic psychedelic use and changes in depressive symptoms.

Journal of Affective Disorders July 9, 2025 Otto Simonsson, Peter S. Hendricks, Caroline M. Swords et al. 8 citations

While growing evidence suggests that psychedelic-assisted therapy may have antidepressant effects in certain populations, little is known about the effects of psychedelic use on depressive symptoms in non-clinical, naturalistic settings. This observational cohort study included a large sample of US residents (18-50 years old) and longitudinally evaluated the relationships between naturalistic...

DOI: 10.1016/j.jad.2025.119857 Full text Depression Increased depressive symptoms Negative outcomes Adverse effects +5

Antidepressant effects of esketamine are associated with functional connectivity in the hippocampal subregion: A resting state magnetic resonance study.

Neuroscience July 8, 2025 Xiang Liu, Yumeng Liu, Jun Tu et al. 2 citations

We aimed to investigate the relationship between changes in resting-state functional connectivity in a subregion of the hippocampus and the antidepressant effects of esketamine as well as to identify potential neuroimaging markers of the treatment outcomes. Twenty-nine patients with major depressive disorder (MDD) received six intravenous infusions of esketamine. All patients completed the...

DOI: 10.1016/j.neuroscience.2025.07.016 Full text Esketamine Major depressive disorder Mdd Functional connection +14

Research